NCT06687681View on ClinicalTrials.gov

Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

November 25, 2025

Study Completion Date

November 25, 2027

Conditions
Glioma Glioblastoma MultiformeHigh Grade Glioma (III or IV)
Interventions
BIOLOGICAL

NK cell therapy

Active NK cell injection through lumbar puncture in patient with Astrocytoma IDH-mutant, Oligodendroglioma IDHmutant, Glioblastoma IDH-wild type, Diffuse midline glioma, Diffuse hemispheric glioma, Diffuse pediatrictype high-grade glioma IDH-wild type

Trial Locations (1)

1343864331

RECRUITING

Rasoul Akram hospital, Tehran

All Listed Sponsors
lead

Marzieh Ebrahimi

INDUSTRY